Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 8/20 | 0.41 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.40 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12628934 | 0.93 | ALDH1A1 (0.45) | LPAR1LPAR3SMN1; SMN2LPAR2ALDH1A1 | |
| SCHEMBL829055 | 0.89 | ALDH1A1 (0.40) | LPAR1LPAR3SMN1; SMN2LPAR2ALDH1A1 | |
| SCHEMBL12990161 | 0.87 | SMN1; SMN2 (0.39) | TLR2LPAR1LPAR3KMT2ASMN1; SMN2 | |
| SCHEMBL13563941 | 0.87 | TLR2 (0.37) | TLR2LPAR1LPAR3KMT2ASMN1; SMN2 | |
| SCHEMBL22667645 | 0.86 | TLR2 (0.46) | TLR2LPAR1LPAR3LPAR2 | |
| SCHEMBL15686246 | 0.85 | TLR2 (0.34) | TLR2LPAR1LPAR3LPAR2 | |
| SCHEMBL14985548 | 0.84 | USP2 (0.37) | KMT2ASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL14401860 | 0.83 | LPAR6 (0.37) | LPAR1LPAR3SMN1; SMN2LPAR2ALDH1A1 | |
| SCHEMBL13369011 | 0.83 | LPAR5 (0.37) | LPAR1LPAR3KMT2ASMN1; SMN2LPAR2 | |
| SCHEMBL10196084 | 0.82 | TLR2 (0.32) | TLR2LPAR1LPAR3ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170240590-A1 | NUCLEOPHILIC CATALYSTS FOR OXIME LINKAGE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-24 | — | — | US | disclosed |
| US-9731024-B2 | Nucleophilic catalysts for oxime linkage | BAXALTA INCORPORATED (US) | 2017-08-15 | — | — | US | disclosed |
| US-20160058842-A1 | FACTOR VIII POLYMER CONJUGATES | BAXTER INTERNATIONAL INC. | 2016-03-03 | — | — | US | disclosed |
| US-20150024455-A1 | NUCLEOPHILIC CATALYSTS FOR OXIME LINKAGE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-01-22 | — | — | US | disclosed |
| US-8809501-B2 | Nucleophilic catalysts for oxime linkage | BAXTER INTERNATIONAL INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8637640-B2 | Blood coagulation protein conjugates | BAXTER INTERNATIONAL INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20130011900-A1 | NUCLEOPHILIC CATALYSTS FOR OXIME LINKAGE | BAXTER HEALTHCARE S.A. (CH) | 2013-01-10 | — | — | US | disclosed |
| US-20120309021-A1 | DETECTION OF ANTIBODY THAT BINDS TO WATER SOLUBLE POLYMER-MODIFIED POLYPEPTIDES | BAXTER INTERNATIONAL INC. (US) | 2012-12-06 | — | — | US | disclosed |
| US-20120232252-A1 | FACTOR VIII POLYMER CONJUGATES | BAXTER INTERNATIONAL INC. (US) | 2012-09-13 | — | — | US | disclosed |
| US-8216793-B2 | Detection of antibody that binds to water soluble polymer-modified polypeptides | BAXTER INTERNATIONAL INC. (US) | 2012-07-10 | — | — | US | disclosed |
| US-20100173830-A1 | FACTOR VIII POLYMER CONJUGATES | BAXTER HEALTHCARE S.A. (CH) | 2010-07-08 | — | — | US | disclosed |
| US-20100173831-A1 | FACTOR VIII POLYMER CONJUGATES | BAXTER HEALTHCARE S.A. (CH) | 2010-07-08 | — | — | US | disclosed |
| US-20100168391-A1 | Pegylated Factor VIII | BAXTER INTERNATIONAL INC. (US) | 2010-07-01 | — | — | US | disclosed |
| US-20100113364-A1 | FACTOR VIII POLYMER CONJUGATES | BAXTER HEALTHCARE S.A. (CH) | 2010-05-06 | — | — | US | disclosed |
| US-20100113365-A1 | FACTOR VIII POLYMER CONJUGATES | BAXTER HEALTHCARE S.A. (CH) | 2010-05-06 | — | — | US | disclosed |
| US-20100093934-A1 | PEGYLATION OF RECOMBINANT BLOOD COAGULATION FACTORS IN THE PRESENCE OF BOUND ANTIBODIES | BAXTER INTERNATIONAL INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-7683158-B2 | Pegylated factor VIII | BAXTER INTERNATIONAL INC. (US) | 2010-03-23 | — | — | US | disclosed |
| US-7645860-B2 | Factor VIII polymer conjugates | BAXTER HEALTHCARE S.A. (CH) | 2010-01-12 | — | — | US | disclosed |
| US-20090076237-A1 | Factor VIII Polymer Conjugates | BAXTER HEALTHCARE S.A. (CH) | 2009-03-19 | — | — | US | disclosed |
| US-20070244301-A1 | Pegylated factor VIII | WELLS FARGO BANK, NATIONAL ASSOCIATION | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170240590-A1 | NUCLEOPHILIC CATALYSTS FOR OXIME LINKAGE | LPO, OGA, DAO | TLR2 2159/4885LPAR1 4103/4885LPAR3 4271/4885 |
| US-20100093934-A1 | PEGYLATION OF RECOMBINANT BLOOD COAGULATION FACTORS IN THE PRESENCE OF BOUND ANTIBODIES | F8, F13B, F13A1 | TLR2 3848/4885LPAR1 2583/4885LPAR3 3162/4885 |
| US-20130011900-A1 | NUCLEOPHILIC CATALYSTS FOR OXIME LINKAGE | LPO, OGA, DAO | TLR2 2159/4885LPAR1 4103/4885LPAR3 4271/4885 |
| US-20100173830-A1 | FACTOR VIII POLYMER CONJUGATES | F8, F13B, F13A1 | TLR2 3836/4885LPAR1 4216/4885LPAR3 4206/4885 |
| US-20100173831-A1 | FACTOR VIII POLYMER CONJUGATES | F8, F13B, F13A1 | TLR2 3836/4885LPAR1 4216/4885LPAR3 4206/4885 |
| US-20090076237-A1 | Factor VIII Polymer Conjugates | F8, F13B, F13A1 | TLR2 3836/4885LPAR1 4216/4885LPAR3 4206/4885 |
| US-20100113365-A1 | FACTOR VIII POLYMER CONJUGATES | F8, F13B, F13A1 | TLR2 3836/4885LPAR1 4216/4885LPAR3 4206/4885 |
| US-20150024455-A1 | NUCLEOPHILIC CATALYSTS FOR OXIME LINKAGE | LPO, OGA, DAO | TLR2 2159/4885LPAR1 4103/4885LPAR3 4271/4885 |
| US-20070244301-A1 | Pegylated factor VIII | F8, F13B, F7 | TLR2 3930/4885LPAR1 3416/4885LPAR3 3522/4885 |
| US-20100168391-A1 | Pegylated Factor VIII | F8, F13B, F7 | TLR2 3930/4885LPAR1 3416/4885LPAR3 3522/4885 |
| US-20120232252-A1 | FACTOR VIII POLYMER CONJUGATES | F8, F13B, F13A1 | TLR2 3836/4885LPAR1 4216/4885LPAR3 4206/4885 |
| US-20100113364-A1 | FACTOR VIII POLYMER CONJUGATES | F8, F13B, F13A1 | TLR2 3836/4885LPAR1 4216/4885LPAR3 4206/4885 |
| US-20160058842-A1 | FACTOR VIII POLYMER CONJUGATES | F8, F13B, F13A1 | TLR2 3836/4885LPAR1 4216/4885LPAR3 4206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.